Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients

Ye Ying Cen, Donald D. Glower, Kevin Landolfo, James E. Lowe, R. Duane Davis, Walter G. Wolfe, Carl Pieper, Bercedis Peterson

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: We sought to compare 10-year survival in patients after mitral valve replacement with biologic or mechanical valve prostheses. Methods: Retrospective survival analysis was performed on data from 1139 consecutive patients older than 18 years of age undergoing mitral valve replacement with Carpentier-Edwards (n = 495; Baxter Healthcare Corp, Irvine, Calif) or St Jude Medical (n = 644; St Jude Medical, Inc, St Paul, Minn) prostheses. Results: The 10-year survival was not statistically different between the patients receiving Carpentier-Edwards valves and those receiving St Jude Medical valves (P = .16). Adjusted survival estimates at 2, 5, and 10 years were 82% ±2% (95% confidence intervals, 79%-85%), 69% ± 2% (95% confidence intervals, 64%-73%), and 42% ± 3% (95% confidence intervals, 37%-48%), respectively, for the Carpentier-Edwards group and 83%±2% (95% confidence intervals, 80%-86%), 72%± 2% (95% confidence intervals, 69%-76%), and 51% ±3% (95% confidence intervals, 45%-58%), respectively, for the St Jude Medical group. Predictors of worse survival after mitral valve replacement are older age, lower ejection fraction, presence of class IV congestive heart failure, coronary artery disease, renal disease, smoking history, hypertension, concurrent other valve surgery, and redo heart surgery. Conclusion: Choice of biologic or mechanical prosthesis does not significantly affect long-term patient survival after mitral valve replacement.

Original languageEnglish (US)
Pages (from-to)569-577
Number of pages9
JournalJournal of Thoracic and Cardiovascular Surgery
Volume122
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Mitral Valve
Confidence Intervals
Survival
Prostheses and Implants
Survival Analysis
Thoracic Surgery
Coronary Artery Disease
Heart Failure
Smoking
History
Hypertension
Delivery of Health Care
Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Cen, Y. Y., Glower, D. D., Landolfo, K., Lowe, J. E., Davis, R. D., Wolfe, W. G., ... Peterson, B. (2001). Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients. Journal of Thoracic and Cardiovascular Surgery, 122(3), 569-577. https://doi.org/10.1067/mtc.2001.115418

Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients. / Cen, Ye Ying; Glower, Donald D.; Landolfo, Kevin; Lowe, James E.; Davis, R. Duane; Wolfe, Walter G.; Pieper, Carl; Peterson, Bercedis.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 122, No. 3, 2001, p. 569-577.

Research output: Contribution to journalArticle

Cen, YY, Glower, DD, Landolfo, K, Lowe, JE, Davis, RD, Wolfe, WG, Pieper, C & Peterson, B 2001, 'Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients', Journal of Thoracic and Cardiovascular Surgery, vol. 122, no. 3, pp. 569-577. https://doi.org/10.1067/mtc.2001.115418
Cen, Ye Ying ; Glower, Donald D. ; Landolfo, Kevin ; Lowe, James E. ; Davis, R. Duane ; Wolfe, Walter G. ; Pieper, Carl ; Peterson, Bercedis. / Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients. In: Journal of Thoracic and Cardiovascular Surgery. 2001 ; Vol. 122, No. 3. pp. 569-577.
@article{0adf78e921e94232b07230ea7c256603,
title = "Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients",
abstract = "Objective: We sought to compare 10-year survival in patients after mitral valve replacement with biologic or mechanical valve prostheses. Methods: Retrospective survival analysis was performed on data from 1139 consecutive patients older than 18 years of age undergoing mitral valve replacement with Carpentier-Edwards (n = 495; Baxter Healthcare Corp, Irvine, Calif) or St Jude Medical (n = 644; St Jude Medical, Inc, St Paul, Minn) prostheses. Results: The 10-year survival was not statistically different between the patients receiving Carpentier-Edwards valves and those receiving St Jude Medical valves (P = .16). Adjusted survival estimates at 2, 5, and 10 years were 82{\%} ±2{\%} (95{\%} confidence intervals, 79{\%}-85{\%}), 69{\%} ± 2{\%} (95{\%} confidence intervals, 64{\%}-73{\%}), and 42{\%} ± 3{\%} (95{\%} confidence intervals, 37{\%}-48{\%}), respectively, for the Carpentier-Edwards group and 83{\%}±2{\%} (95{\%} confidence intervals, 80{\%}-86{\%}), 72{\%}± 2{\%} (95{\%} confidence intervals, 69{\%}-76{\%}), and 51{\%} ±3{\%} (95{\%} confidence intervals, 45{\%}-58{\%}), respectively, for the St Jude Medical group. Predictors of worse survival after mitral valve replacement are older age, lower ejection fraction, presence of class IV congestive heart failure, coronary artery disease, renal disease, smoking history, hypertension, concurrent other valve surgery, and redo heart surgery. Conclusion: Choice of biologic or mechanical prosthesis does not significantly affect long-term patient survival after mitral valve replacement.",
author = "Cen, {Ye Ying} and Glower, {Donald D.} and Kevin Landolfo and Lowe, {James E.} and Davis, {R. Duane} and Wolfe, {Walter G.} and Carl Pieper and Bercedis Peterson",
year = "2001",
doi = "10.1067/mtc.2001.115418",
language = "English (US)",
volume = "122",
pages = "569--577",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients

AU - Cen, Ye Ying

AU - Glower, Donald D.

AU - Landolfo, Kevin

AU - Lowe, James E.

AU - Davis, R. Duane

AU - Wolfe, Walter G.

AU - Pieper, Carl

AU - Peterson, Bercedis

PY - 2001

Y1 - 2001

N2 - Objective: We sought to compare 10-year survival in patients after mitral valve replacement with biologic or mechanical valve prostheses. Methods: Retrospective survival analysis was performed on data from 1139 consecutive patients older than 18 years of age undergoing mitral valve replacement with Carpentier-Edwards (n = 495; Baxter Healthcare Corp, Irvine, Calif) or St Jude Medical (n = 644; St Jude Medical, Inc, St Paul, Minn) prostheses. Results: The 10-year survival was not statistically different between the patients receiving Carpentier-Edwards valves and those receiving St Jude Medical valves (P = .16). Adjusted survival estimates at 2, 5, and 10 years were 82% ±2% (95% confidence intervals, 79%-85%), 69% ± 2% (95% confidence intervals, 64%-73%), and 42% ± 3% (95% confidence intervals, 37%-48%), respectively, for the Carpentier-Edwards group and 83%±2% (95% confidence intervals, 80%-86%), 72%± 2% (95% confidence intervals, 69%-76%), and 51% ±3% (95% confidence intervals, 45%-58%), respectively, for the St Jude Medical group. Predictors of worse survival after mitral valve replacement are older age, lower ejection fraction, presence of class IV congestive heart failure, coronary artery disease, renal disease, smoking history, hypertension, concurrent other valve surgery, and redo heart surgery. Conclusion: Choice of biologic or mechanical prosthesis does not significantly affect long-term patient survival after mitral valve replacement.

AB - Objective: We sought to compare 10-year survival in patients after mitral valve replacement with biologic or mechanical valve prostheses. Methods: Retrospective survival analysis was performed on data from 1139 consecutive patients older than 18 years of age undergoing mitral valve replacement with Carpentier-Edwards (n = 495; Baxter Healthcare Corp, Irvine, Calif) or St Jude Medical (n = 644; St Jude Medical, Inc, St Paul, Minn) prostheses. Results: The 10-year survival was not statistically different between the patients receiving Carpentier-Edwards valves and those receiving St Jude Medical valves (P = .16). Adjusted survival estimates at 2, 5, and 10 years were 82% ±2% (95% confidence intervals, 79%-85%), 69% ± 2% (95% confidence intervals, 64%-73%), and 42% ± 3% (95% confidence intervals, 37%-48%), respectively, for the Carpentier-Edwards group and 83%±2% (95% confidence intervals, 80%-86%), 72%± 2% (95% confidence intervals, 69%-76%), and 51% ±3% (95% confidence intervals, 45%-58%), respectively, for the St Jude Medical group. Predictors of worse survival after mitral valve replacement are older age, lower ejection fraction, presence of class IV congestive heart failure, coronary artery disease, renal disease, smoking history, hypertension, concurrent other valve surgery, and redo heart surgery. Conclusion: Choice of biologic or mechanical prosthesis does not significantly affect long-term patient survival after mitral valve replacement.

UR - http://www.scopus.com/inward/record.url?scp=0034850291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034850291&partnerID=8YFLogxK

U2 - 10.1067/mtc.2001.115418

DO - 10.1067/mtc.2001.115418

M3 - Article

C2 - 11547311

AN - SCOPUS:0034850291

VL - 122

SP - 569

EP - 577

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 3

ER -